Search research articles
Contact Us
Filters
Showing results (41-50 of 70) with videos related to
Page
of 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2017
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
Yong-Chen Lu, Linda L Parker, Tangying Lu, et al.
Nature Communications
|
October 6, 2024
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency
Justin A Guerrero, Dorota D Klysz, Yiyun Chen, et al.
Blood
|
December 14, 2011
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N Kochenderfer, Mark E Dudley, Steven A Feldman, et al.
JCI Insight
|
December 8, 2017
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy
Christopher A Klebanoff, Joseph G Crompton, Anthony J Leonardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2017
Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
Yasmine Assadipour, Nikolaos Zacharakis, Jessica S Crystal, et al.
Blood Cancer Discovery
|
December 18, 2025
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome
Hrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2015
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma
Ling Zhang, Richard A Morgan, Joal D Beane, et al.
Lancet (London, England)
|
July 12, 2024
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
Matthew J Frank, John H Baird, Anne Marijn Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2018
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N Brudno, Irina Maric, Steven D Hartman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
May 6, 2015
Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma
Joal D Beane, Gary Lee, Zhili Zheng, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 70) with videos related to
Sort By:
Page
of 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2017
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
Yong-Chen Lu, Linda L Parker, Tangying Lu, et al.
Nature Communications
|
October 6, 2024
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency
Justin A Guerrero, Dorota D Klysz, Yiyun Chen, et al.
Blood
|
December 14, 2011
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N Kochenderfer, Mark E Dudley, Steven A Feldman, et al.
JCI Insight
|
December 8, 2017
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy
Christopher A Klebanoff, Joseph G Crompton, Anthony J Leonardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2017
Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
Yasmine Assadipour, Nikolaos Zacharakis, Jessica S Crystal, et al.
Blood Cancer Discovery
|
December 18, 2025
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome
Hrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2015
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma
Ling Zhang, Richard A Morgan, Joal D Beane, et al.
Lancet (London, England)
|
July 12, 2024
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
Matthew J Frank, John H Baird, Anne Marijn Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2018
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N Brudno, Irina Maric, Steven D Hartman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
May 6, 2015
Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma
Joal D Beane, Gary Lee, Zhili Zheng, et al.
Page
of 7